— Competitive Grant Program to Offer
Individual Grants of Up to $100,000
per Project —
— Application Period to Run From
Sept. 20, 2024 Through Nov. 30, 2024 —
DUBLIN, Sept. 13, 2024 /PRNewswire/ -- Alkermes plc
(Nasdaq: ALKS) today announced that it will begin accepting
applications for its annual Alkermes Pathways Research
Awards® program on Friday, Sept.
20, 2024. Now in its seventh year, this competitive grant
program is designed to support the next generation of researchers
working on the front lines to advance our understanding of diseases
in the field of neuroscience. The program will offer grants to
early-career investigators who have demonstrated a commitment to
advancing research related to schizophrenia or bipolar disorder.
The application period will run through Nov.
30, 2024.
"The Alkermes Pathways Research Awards program is one example of
our commitment to the pursuit of great science in the field of
neuroscience. With 25 awards presented since 2018, we are proud of
the impact that the Pathways program has made to support
early-career researchers dedicated to advancing our shared
understanding of complex psychiatric conditions, some of whom have
received grants from the NIH based, in part, on their
Pathways-funded research," said Craig
Hopkinson, M.D., Chief Medical Officer and Executive Vice
President of Research and Development at Alkermes.
The 7th annual Alkermes Pathways Research Awards program will
offer grants in amounts of up to $100,000 per project. To qualify, early-career
investigators must be M.D.s, Ph.D.s, or equivalent, who are within
five years of their initial academic appointment or are current
post-doctoral fellows, and who are affiliated with a medical or
research institution within the United
States. Applicants will be evaluated by an independent
review committee comprised of specialists in psychiatry,
neurobiology, pharmacology, and behavioral science from academic
research centers.
The Alkermes Pathways Research Awards program began in 2018 and
has since provided approximately $2.5
million in funding to 25 researchers across the United States. To date, research funded by
the Pathways program has resulted in multiple journal publications,
oral presentations and posters. Award recipients have undertaken
important, mentor-supported research to help advance the field of
neuroscience. For more information on the Alkermes Pathways
Research Awards program, including full eligibility criteria and
how to apply for the 7th annual edition of the program, visit
www.PathwaysResearchAwards.com.
About Alkermes plc
Alkermes plc is a global
biopharmaceutical company that seeks to develop innovative
medicines in the field of neuroscience. The company has a portfolio
of proprietary commercial products for the treatment of alcohol
dependence, opioid dependence, schizophrenia and bipolar I
disorder, and a pipeline of clinical and preclinical candidates in
development for neurological disorders, including narcolepsy.
Headquartered in Ireland, Alkermes
also has a corporate office and research and development center in
Massachusetts and a manufacturing
facility in Ohio. For more
information, please visit Alkermes' website at
www.alkermes.com.
Alkermes Pathways Research Awards® is a registered
service mark of Alkermes, Inc. The Alkermes Pathways Research
Awards logo is a service mark of Alkermes, Inc.
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781
609 6377
For Media: Gretchen Murphy, +1
781 609 6419
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/alkermes-announces-launch-of-7th-annual-alkermes-pathways-research-awards-program-302247367.html